It is chasing after Vertex Pharma’s VX-548 ... Surveyor Capital, Medicxi, Logos Capital, Octagon Capital, Piper Heartland Healthcare Capital, and LifeSci Venture Partners, along with existing ...

SillaJen researchers work on anti-cancer drugs (Courtesy of SillaJen) Qureator was co-founded by Jeon Noo-li, a mechanical engineering professor at Seoul National University and a leading expert in ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...

Jim Cramer continues to show his support for the biotech company, as evident by his most recent comments from the 14 th of ...